Bionano Genomics Announces its Participation at the Cancer Genomics Consortium 2022 Annual Meeting with 18 OGM Presentations Covering the Cancer Genomics Landscape
July 26 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the Cancer Genomics Consortium (CGC) 2022 Annual
Meeting with 18 events including a panel discussion, scientific
platform presentations, facilitated roundtable, and poster
presentations from Bionano and a wide variety of independent
researchers from across the cancer genomics landscape.
CGC’s Annual Meeting brings together industry, medical, and
academic professionals to discuss advances in clinical genomics for
cancer research. CGC conference sessions will take place July
31- August 3, 2022, in St. Louis, Missouri with an option for
virtual attendance. Bionano will exhibit its complete portfolio of
products and services relevant to the cancer research community
including OGM solutions, NxClinical™ software and laboratory
services.
As part of a sponsored spotlight panel, Bionano’s chief medical
officer, Alka Chaubey, will host a discussion titled “Optical
Genome Mapping and its Integration with NGS for Clinical Research
in Leukemia and Lymphoma,” featuring cancer genomics experts
Dr. Ravindra Kolhe, from the Medical College of
Georgia/Augusta University, Dr. Yassmine Akkari, from Nationwide
Children’s Hospital, Dr. Rashmi Kanagal-Shamanna, from MD Anderson
Cancer Center, and Dr. Brynn Levy, from Columbia University Medical
Center and the New York Presbyterian Hospital. The presentation
will take place Tuesday, August 2, from 4:45-5:30 PM CST in the
General Session room.
Four separate scientific presentations, featuring the use of OGM
in cancer research will be given. Dr. Adam Smith of University
Health Network will present on international working group
recommendations for the use of OGM in hematological malignancy
research. Dr. Ha Nguyen of MD Anderson Cancer
Center will present on homologous recombination DNA repair
deficiency in hematological malignancies. Dr. Thuy Phung of
University of South Alabama will present on the identification of
novel structural variants (SVs) in angiosarcoma using OGM. Dr.
Nikhil Sahajpal of Augusta University will present on the
integration of OGM and a 523-gene panel for comprehensive genomic
evaluation of myeloid cancers. Dr. Smith will also facilitate a
roundtable discussion on the detection of gene rearrangements by
OGM and NGS.
In addition, 12 posters featuring results from OGM applications
in cytogenetics and cancer research will be presented at the
conference. The full content of the posters will be made available
on the Bionano Genomics website once presented at the
conference. More details on the conference can be found here.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Session |
Title |
Presenter |
Presented |
Session 1: Integrating Novel Genomic Alterations
for Pathologic Classification and Clinical Risk Assessment in
Pediatric and Adult Leukemias |
Homologous Recombination DNA Repair Deficiency in Hematological
Malignancies |
Nguyen H. |
July 31, 20221:15-2:20 PM |
Session 5: Implementation of New and Emerging
Technologies in Oncologic Laboratories for Improving Patient
Care |
International Working Group Recommendations for the Implementation
of Optical Genome Mapping in Hematologic Malignancies |
Smith A. |
August 1, 20228:00-9:00 AM |
Session 7: Application of High-Depth and Novel
Genomic Testing Methodologies in the Comprehensive Analyses of
Vascular Anomalies and Somatic Mosaic Disorders |
Identification of Novel Genomic Structural Variations in
Angiosarcoma by Optical Genome Mapping |
Phung T. |
August 1, 20222:15-3:15 PM |
Round Table Session |
Detection of Gene Rearrangements by Next Generation Sequencing
(NGS) and Optical Genome Mapping |
Smith A. |
August 2, 202212:50-2:00 PM |
Session 11: Expanded Horizons in Hematologic
Malignancies: Clonal Behaviors and Novel Genomic
Approaches |
Optical Genome Mapping and 523-Gene Sequencing Panel for
Comprehensive Genomic Evaluation of Myeloid Cancers |
Sahajpal N. |
August 2, 20223:00-4:00 PM |
Diamond Vendor Showcase: Bionano Genomics |
Optical Genome Mapping and its Integration with NGS for Clinical
Research in Leukemia and Lymphoma |
Chaubey A. |
August 2, 20224:45-5:30 PM |
Poster Title |
Author |
Optical Genome Mapping Workflow for Somatic Abnormality Detection
in Multiple Solid Tumor Types |
Hastie A. |
Use of Optical Genome Mapping and Next Generation Sequencing to
Construct a Comprehensive Somatic Variation Map in a Cancer Cell
Line |
Pang A. |
Comparison of Optical Genome Mapping, CMA, and 523-gene NGS panel
for Homologous Recombination Deficiency Calculation |
Sahajpal N. |
Optical Genome Mapping: Clinical Validation and Diagnostic Utility
for Cytogenomic Analysis of Hematological Neoplasms |
Sahajpal N. |
Concordance of Integrated Analysis Approaches to Measure Genomic
Instability Associated with Homologous Recombination Deficiency
(HRD) Using TCGA Ovarian Cancer Dataset |
Shams S. |
Optical Genome Mapping Workflow for Identification and Analysis of
Variants in Hematological Malignancies |
Yu J. |
Optical Genome Mapping Reveals Novel Structural Variants in
Pediatric Brain Tumors |
Bornhorst M. |
Optical Genome Mapping for Somatic Abnormality Detection in
Multiple Solid Tumor Types |
Clifford B. |
Optical Genome Mapping: Unravelling the Genomic Landscape of
Solitary Fibrous Tumor |
Salguero-Aranda C. |
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter
Evaluation |
Levy B. |
Optical Genome Mapping for Constitutional Postnatal SV, CNV, and
Repeat Array Sizing: A Multi-site Clinical Study |
Sahajpal N. |
Optical Genome Mapping and NGS for Identification of All Classes of
Variants |
Yu J. |
“Bionano attended its first CGC conference six years ago, with
only a few sales representatives and our scientific affairs
director in attendance. During the meeting, we recognized that OGM
could have a significant impact on cancer genomic research. This
year’s CGC meeting, with the greatest number of presentations
featuring OGM to date, illustrates the importance of it in cancer
research. We are excited to see how much more of an impact OGM may
make in the future,” commented Erik Holmlin, PhD, president and
chief executive officer of Bionano Genomics.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “could,” “may,” and similar expressions (as
well as other words or expressions referencing future events,
conditions, or circumstances) convey uncertainty of future events
or outcomes are intended to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability and
utility of OGM to impact cancer research, or to integrate with next
generation sequencing (NGS) to provide a more comprehensive
analysis of the genome for applications in cancer research. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of the COVID-19 pandemic
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements to existing technologies;
failure OGM to achieve useful complementarity with NGS; future
study results contradicting the results reported in the
presentations given and posters made available at the CGC 2022
Annual Meeting; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1
(858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024